Standard Biotools Inc.
A maker of scientific instruments used by biomedical researchers to study individual cells and proteins. Its three platforms—CyTOF mass cytometry, Hyperion spatial proteomics, and Biomark genomics—are sold to academic labs, translational centers, and biopharma companies. Founded in 1999 as Mycometrix and renamed Fluidigm in 2001 (a play on the "fluid" microchips it builds), the company became Standard BioTools in 2022, after its microfluidics "integrated fluidic circuits" were born from a Caltech lab that manipulates fluids on chips much like electronics handle electrons.
Granted 58.2K · Bought 10.92M
Granted 46.47M · Bought 2.30M
Bought 12.71M
Granted 21.93M · Bought 1.20M
Bought 3.06M
Granted 13.99M
Granted 7.24M · Sold 15.3K
Granted 2.85M · Sold 4.2K
Granted 1.05M · Sold 38.6K
Bought 1.20M
Granted 460.5K
Granted 365.8K · Bought 86.0K
Granted 145.6K
Granted 423.9K
Granted 335.3K
Granted 44.8K
Granted 310.0K
Granted 316.2K
Granted 26.0K
Granted 57.3K
Granted 57.3K
Granted 104.4K
Granted 40.4K
Granted 57.8K
Granted 30.9K
Granted 13.0K
Granted 30.9K
Granted 20.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Casdin Eli +8 co-filersDirector, 10% owner, Director, 10% owner · 17 transactions | — | 136.13Mas of Mar 2025 | 58.2K | 10.92M | — |
| Casdin Eli +8 co-filersDirector, Director, 10% owner · 14 transactions | — | 130.66Mas of Jun 2024 | 46.47M | 2.30M | — |
| Casdin Eli +7 co-filersDirector, Director, 10% owner · 24 transactions | — | 105.62M | — | 12.71M | — |
| Casdin EliDirector, 10% owner · 17 transactions | — | 91.84M | 21.93M | 1.20M | — |
| Caligan Partners LP +1 co-filer10% owner · 20 transactions | — | 19.24Mas of Jul 2023 | — | 3.06M | — |
| Casdin Private Growth Equity Fund GP, LLC +7 co-filersDirector, Director, 10% owner · 2 transactions | — | 15.19Mas of Jan 2024 | 13.99M | — | — |
| Caligan Partners LP10% owner · 1 transaction | — | 8.58Mas of Dec 2022 | — | — | — |
| Egholm MichaelPresident & CEO, Director · 26 transactions | — | 6.14M | 7.24M | — | 15.3K |
| Kim Hanjoon AlexChief Financial Officer · 21 transactions | — | 2.53M | 2.85M | — | 4.2K |
| Mackay SeanSVP & Chief Business Officer · 12 transactions | — | 1.48M | 1.05M | — | 38.6K |
| Casdin Capital, LLC +5 co-filersDirector, 10% owner, Director · 3 transactions | — | 1.20Mas of May 2023 | — | 1.20M | — |
| Cox TroyDirector · 7 transactions | — | 475.7K | 460.5K | — | — |
| Black Jeffrey G.SVP & Chief Financial Officer · 8 transactions | — | 421.6Kas of Aug 2024 | 365.8K | 86.0K | — |
| Jog VikramChief Financial Officer · 28 transactions | — | 350.5Kas of Feb 2023 | 145.6K | — | — |
| Carey Thomas D.Director · 6 transactions | — | 344.5K | 423.9K | — | — |
| Eloi Fenel MDirector · 5 transactions | — | 335.3K | 335.3K | — | — |
| Linthwaite Stephen ChristopherPresident & CEO · 8 transactions | +7.3% | 326.3Kas of Feb 2022 | 44.8K | — | — |
| Witney FrankDirector · 6 transactions | — | 314.2K | 310.0K | — | — |
| Hibbs Kathy LDirector · 4 transactions | — | 236.8K | 316.2K | — | — |
| Barthelemy NicolasDirector · 2 transactions | +14.6% | 204.1Kas of Apr 2022 | 26.0K | — | — |
| Paya Carlos VDirector · 2 transactions | +82.4% | 126.8Kas of Jun 2023 | 57.3K | — | — |
| Clague LauraDirector · 2 transactions | +120.6% | 104.8Kas of Jun 2023 | 57.3K | — | — |
| Madaus Martin DDirector · 5 transactions | — | 104.1Kas of Oct 2023 | 104.4K | — | — |
| Khadder NicholasSVP, Gen. Counsel & Secretary · 9 transactions | +26.9% | 100.5Kas of May 2022 | 40.4K | — | — |
| Kreger Bradley AllenSVP, Global Operations · 14 transactions | +24.3% | 99.1Kas of May 2022 | 57.8K | — | — |
| Burbach Gerhard FDirector · 1 transaction | +46.9% | 96.8Kas of Jun 2022 | 30.9K | — | — |
| McCracken ColinChief Commercial Officer · 8 transactions | +10.5% | 65.1Kas of Feb 2022 | 13.0K | — | — |
| Colston BillDirector · 1 transaction | +109% | 59.3Kas of Jun 2022 | 30.9K | — | — |
| Davis Jeremy StevenSVP Chief Commercial Officer · 2 transactions | — | 14.7Kas of Feb 2023 | 20.8K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +31.42M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.